John Miya, Ford Caroline E
Gynaecological Cancer Research Group, Lowy Cancer Research Centre, School of Women's and Children's Health, Faculty of Medicine and Health, University of New South Wales, Cnr High and Botany St., Kensington, Sydney, NSW 2052, Australia.
Biomedicines. 2022 Oct 13;10(10):2559. doi: 10.3390/biomedicines10102559.
ROR1/2 are putative druggable targets increasing in significance in translational oncology. Expression of ROR1/2 mRNA and transcript variants has not been systematically examined thus far. ROR1/2 transcript variant sequences, signal peptides for cell surface localisation, and mRNA and transcript variant expression were examined in 34 transcriptomic datasets including 33 cancer types and 54 non-diseased human tissues. ROR1/2 have four and eight transcript variants, respectively. ROR1/2 mRNA and transcript variant expression was detected in various non-diseased tissues. Our analysis identifies predominant expression of ROR1 transcript variant ENST00000545203, which lacks a signal peptide for cell surface localisation, rather than the predicted principal variant ENST00000371079. ENST00000375708 is the predominantly expressed transcript variant of ROR2. ROR1/2 expression in healthy human tissues should be carefully considered for safety assessment of targeted therapy. Studies exploring the function and significance of the predominantly expressed ROR1 transcript variant ENST00000545203 are warranted.
ROR1/2是在转化肿瘤学中重要性日益增加的潜在可成药靶点。迄今为止,尚未对ROR1/2 mRNA及转录本变体的表达进行系统研究。在包括33种癌症类型和54种非病变人体组织的34个转录组数据集中,对ROR1/2转录本变体序列、细胞表面定位的信号肽以及mRNA和转录本变体表达进行了检测。ROR1/2分别有4种和8种转录本变体。在各种非病变组织中检测到了ROR1/2 mRNA和转录本变体表达。我们的分析确定ROR1转录本变体ENST00000545203为主导表达,该变体缺乏细胞表面定位的信号肽,而非预测的主要变体ENST00000371079。ENST00000375708是ROR2的主要表达转录本变体。在对靶向治疗进行安全性评估时,应仔细考虑ROR1/2在健康人体组织中的表达。有必要开展研究探索主要表达的ROR1转录本变体ENST00000545203的功能及意义。